Health systems are putting money into remote patient monitoring. That is the real story behind Cadence’s new $100 million funding round. Spark Capital led it.
But the investors also include Memorial Hermann and Duke Health. Those are not venture firms.
Those are hospitals. They treat patients every day. The money goes to Cadence, a company that builds remote patient monitoring platforms.
The platform covers hypertension, type 2 diabetes, heart failure and chronic obstructive pulmonary disease. Four conditions that together affect tens of millions of people.
Managing them typically means regular clinic visits, vital sign checks, medication adjustments. Cadence’s system lets patients do some of that at home. They track their own data and share it with care teams.
Early evidence on these platforms is still developing. That is what the company says. The encouraging part is that health systems themselves are investing.
That suggests they see something working. Memorial Hermann and Duke Health are not writing checks for a science experiment.
They are betting on a tool they may already use or plan to use. Cadence plans to spend the money on expansion. It wants to push its technology and services across more health systems.
It also intends to advance AI agents. And grow value-based care models.
AI agents in healthcare are still new. Their role in clinical decision-making needs careful study. But the company is moving ahead.
Value-based care is a separate piece of this. Under that model, providers get paid based on patient outcomes, not on how many procedures they do. Remote monitoring fits naturally there.
If a patient can check blood pressure at home and send it to a nurse, the nurse can spot trouble early. That can keep the patient out of the hospital.
That saves money. That improves outcomes. Health systems want that.
The funding round is Series C. That means Cadence is past the early stage.
It has a product. It has customers. It has data.
Now it has $100 million to scale. Spark Capital led the round. Spark is a known venture firm.
But again, the participation of Memorial Hermann and Duke Health is the more telling detail. Those are not passive investors.
They are potential partners and customers. Patients should understand something. Remote monitoring is not a replacement for a doctor.
It is a tool. It helps patients manage their health from home.
But the evidence base is still growing. Patients should talk to their doctor before making any changes to their care routine based on new technologies. That is what the company itself says.
Still, the trend is clear. Chronic conditions require constant management. Frequent clinic visits are hard for many patients.
They have jobs. They have families.
They may live far from a specialist. Remote monitoring offers an alternative. It is not perfect.
It is not proven for everything. But health systems are investing.
That means they see potential. The platform covers hypertension, type 2 diabetes, heart failure and COPD. Those are conditions that require regular monitoring of vital signs and symptoms.
Patients can do that at home now. They can share that data with their care teams. That changes how chronic care works.
Cadence will use the funds to expand its technology and services. It will also advance its AI agents.
AI in healthcare is emerging. Its role requires careful study. But the company is moving forward.
So are health systems. Memorial Hermann and Duke Health are in.
That matters.
